Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • blank2thisone blank2thisone Dec 24, 2012 1:13 PM Flag

    Why did we miss this important line in latest 10q?

    Additionally, in the quarter ended June 30, 2012, we entered into contracts totaling $3.0 million for the manufacturing...

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • did not, but why not reference the entire statement of two sentences?

      "In January 2012, we entered into a contract with our drug supply manufacturer for drug required for our dog toxicology study at a total cost of $1.4 million. Additionally, in the quarter ended June 30, 2012, we entered into contracts totaling $3.0 million for the manufacturing of clinical drug supplies."

      Now we need to debate is what is included in "clinical drug supplies." I am sure that more than one drug will enter into this discussion, even though the CRO/cGMP manufacturer of Arikace liposome is specifically named in the revised INSM investor presentation.

      Longs should buy or hold for the right reasons. Not "half-truth" opinions of Spumpers.

      Sentiment: Buy

      • 1 Reply to rehdvm2004
      • by rehdvm2004.Dec 24, 2012 3:43 PM.PermalinkGo to topic
        .

        did not, but why not reference the entire statement of two sentences?

        "In January 2012, we entered into a contract with our drug supply manufacturer for drug required for our dog toxicology study at a total cost of $1.4 million. Additionally, in the quarter ended June 30, 2012, we entered into contracts totaling $3.0 million for the manufacturing of clinical drug supplies."

        Now we need to debate is what is included in "clinical drug supplies." I am sure that more than one drug will enter into this discussion, even though the CRO/cGMP manufacturer of Arikace liposome is specifically named in the revised INSM investor presentation.

        Longs should buy or hold for the right reasons. Not "half-truth" opinions of Spumpers.

        Sentiment: Buy

    • Here is the context of what you truncated....

      "In January 2012, we entered into a contract with our drug supply manufacturer for drug required for our dog toxicology study at a total cost of $1.4 million. Additionally, in the quarter ended June 30, 2012, we entered into contracts totaling $3.0 million for the manufacturing of clinical drug supplies."

 
INSM
11.81+0.47(+4.14%)May 24 4:00 PMEDT